Thursday, April 2, 2015

Qsymia Dosage

Qsymia Dosage

Generic name: phentermine hydrochloride and topiramate

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

General Dosing and Administration

In adults with an initial BMI of 30 kg/m2 or greater or 27 kg/m2 or greater when accompanied by weight-related co-morbidities such as hypertension, type 2 diabetes mellitus, or dyslipidemia prescribe Qsymia as follows:

  • Take Qsymia once daily in the morning with or without food. Avoid dosing with Qsymia in the evening due to the possibility of insomnia.
  • Start treatment with Qsymia 3.75 mg/23 mg (phentermine 3.75 mg/topiramate 23 mg extended-release) daily for 14 days, after 14 days increase to the recommended dose of Qsymia 7.5 mg/46 mg (phentermine 7.5 mg/topiramate 46 mg extended-release) once daily.
  • Evaluate weight loss after 12 weeks of treatment with Qsymia 7.5 mg/46 mg.

If a patient has not lost at least 3% of baseline body weight on Qsymia 7.5 mg/46 mg, discontinue Qsymia or escalate the dose, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss at the Qsymia 7.5 mg/46 mg dose.

To escalate the dose: Increase to Qsymia 11.25 mg/69 mg (phentermine 11.25 mg/topiramate 69 mg extended-release) daily for 14 days, followed by dosing Qsymia 15 mg/92 mg (phentermine 15 mg/topiramate 92 mg extended-release) once daily.
  • Evaluate weight loss following dose escalation to Qsymia 15 mg/92 mg after an additional 12 weeks of treatment. If a patient has not lost at least 5% of baseline body weight on Qsymia 15 mg/92 mg, discontinue Qsymia as directed, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
  • Qsymia 3.75 mg/23 mg and Qsymia 11.25 mg/69 mg are for titration purposes only.
  • Discontinuing Qsymia

    • Discontinue Qsymia 15 mg/92 mg gradually by taking a dose every other day for at least 1 week prior to stopping treatment altogether, due to the possibility of precipitating a seizure [see Warnings and Precautions (5.12) ].
    Dosing in Patients with Renal Impairment

    In patients with moderate (creatinine clearance [CrCl] greater than or equal to 30 and less than 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment dosing should not exceed Qsymia 7.5 mg/46 mg once daily. Renal impairment is determined by calculating CrCl using the Cockcroft-Gault equation with actual body weight [see Warnings and Precautions (5.13) and Clinical Pharmacology (12.3) ].

    Dosing in Patients with Hepatic Impairment

    Source

    Related Posts:

    • Kyb shocksKYB KYB Corporation produces a variety of ride control, hydraulic, and electronic products for use as original equipment and replacement parts in aut… Read More
    • Chrysler me412Introduction The Chrysler ME412 is a concept supercar in the Asphalt series. Overview "ME412" stands for M id-E ngine 4 -turbo 12 -cylinder. Asphalt… Read More
    • In Praise Of Morganite Engagement RingsIn Praise Of Morganite Engagement Rings Thanks to years of being forced to admire other women's rings at cocktail parties and other social occasions,… Read More
    • Umbilical Cord CareUmbilical Cord Care The umbilical cord transported nutrients from you to your baby throughout your pregnancy. Now he or she has a purplish-blue stump… Read More
    • All About Lawn Aeration and Lawn Improvement TipsAll About Lawn Aeration and Lawn Improvement Tips Top 43 Reasons to Aerate Lawn In the last ten years, I’,ve aerated 8,000  (now 9000) lawns, and… Read More

    0 comments:

    Post a Comment